Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Xospata,XOSPATA2023US,2023,USA,MDV,350,68,48,52,28.5,62,75,0,5,15,40,40,35,30,20,15,10,25,65,22,8,5,12,7,15,45,30,7+3,FLAG-Ida,High-dose Ara-C,5+2,0,0,0,35,60,50,10,40,50,70,
Xospata,XOSPATA2022EU,2022,Germany,Claim Database,420,72,51,49,27.9,58,70,0,8,12,35,45,40,25,20,15,12,28,60,25,10,7,15,9,12,40,28,7+3,FLAG-Ida,High-dose Ara-C,5+2,0,0,0,40,65,55,15,35,50,65,
Xospata,XOSPATA2024JP,2024,Japan,MDV,280,65,45,55,26.5,45,80,0,10,20,30,40,45,20,15,20,15,30,55,20,6,4,10,6,18,50,35,7+3,FLAG-Ida,High-dose Ara-C,5+2,0,0,0,30,55,45,20,30,50,75,
